Literature DB >> 20651186

Radiologic and near-infrared/optical spectroscopic imaging: where is the synergy?

Brian W Pogue1, Frederic Leblond, Venkataramanan Krishnaswamy, Keith D Paulsen.   

Abstract

OBJECTIVE: Optical and radiologic imaging are commonly used in preclinical research, and research into combined instruments for human applications is showing promise. The purpose of this article is to outline the fundamental limitations and advantages and to review the available systems. The emerging developments and future potential will be summarized.
CONCLUSION: Integration of hybrid systems is now routine at the preclinical level and appears in the form of specialized packages in which performance varies considerably. The synergy is commonly focused on using spatial localization from radiographs to provide structural data for spectroscopy; however, applications also exist in which the spectroscopy informs the use of radiologic imaging. Examples of clinical systems under research and development are shown.

Entities:  

Mesh:

Year:  2010        PMID: 20651186      PMCID: PMC2993095          DOI: 10.2214/AJR.10.5002

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  84 in total

Review 1.  Contrast agents in X-ray computed tomography and its applications in oncology.

Authors:  Annemarieke Rutten; Mathias Prokop
Journal:  Anticancer Agents Med Chem       Date:  2007-05       Impact factor: 2.505

2.  Resolution limits for imaging through turbid media with diffuse light.

Authors:  J A Moon; R Mahon; M D Duncan; J Reintjes
Journal:  Opt Lett       Date:  1993-10-01       Impact factor: 3.776

3.  Diffuse optical spectroscopy of breast tissue extended to 1100 nm.

Authors:  Paola Taroni; Andrea Bassi; Daniela Comelli; Andrea Farina; Rinaldo Cubeddu; Antonio Pifferi
Journal:  J Biomed Opt       Date:  2009 Sep-Oct       Impact factor: 3.170

4.  Computer aided automatic detection of malignant lesions in diffuse optical mammography.

Authors:  David R Busch; Wensheng Guo; Regine Choe; Turgut Durduran; Michael D Feldman; Carolyn Mies; Mark A Rosen; Mitchell D Schnall; Brian J Czerniecki; Julia Tchou; Angela DeMichele; Mary E Putt; Arjun G Yodh
Journal:  Med Phys       Date:  2010-04       Impact factor: 4.071

5.  A liposomal contrast agent. Preliminary communication.

Authors:  C Musu; E Felder; B Lamy; M Schneider
Journal:  Invest Radiol       Date:  1988-09       Impact factor: 6.016

Review 6.  Polymeric contrast agents for medical imaging.

Authors:  V P Torchilin
Journal:  Curr Pharm Biotechnol       Date:  2000-09       Impact factor: 2.837

7.  Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience.

Authors:  Daniel Floery; Thomas H Helbich; Christopher C Riedl; Silvia Jaromi; Michael Weber; Sepp Leodolter; Michael H Fuchsjaeger
Journal:  Invest Radiol       Date:  2005-06       Impact factor: 6.016

8.  Time-domain optical mammography SoftScan: initial results.

Authors:  Xavier Intes
Journal:  Acad Radiol       Date:  2005-08       Impact factor: 3.173

9.  Assessing breast tissue density by transillumination breast spectroscopy (TIBS): an intermediate indicator of cancer risk.

Authors:  K M Blackmore; J A Knight; R Jong; L Lilge
Journal:  Br J Radiol       Date:  2007-05-30       Impact factor: 3.039

10.  Breast cancer detection by mapping hemoglobin concentration and oxygen saturation.

Authors:  Xuefeng Cheng; Jian-min Mao; Robin Bush; Daniel B Kopans; Richard H Moore; Maryann Chorlton
Journal:  Appl Opt       Date:  2003-11-01       Impact factor: 1.980

View more
  10 in total

Review 1.  Imaging in pancreatic disease.

Authors:  Julien Dimastromatteo; Teresa Brentnall; Kimberly A Kelly
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-09       Impact factor: 46.802

2.  Neurological imaging: statistics behind the pictures.

Authors:  Ivo D Dinov
Journal:  Imaging Med       Date:  2011-08-01

Review 3.  Near-infrared optical mammography for breast cancer detection with intrinsic contrast.

Authors:  Sergio Fantini; Angelo Sassaroli
Journal:  Ann Biomed Eng       Date:  2011-10-05       Impact factor: 3.934

4.  Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.

Authors:  Regine Choe; Turgut Durduran
Journal:  IEEE J Sel Top Quantum Electron       Date:  2011-12-02       Impact factor: 4.544

5.  Early detection of heterotopic ossification using near-infrared optical imaging reveals dynamic turnover and progression of mineralization following Achilles tenotomy and burn injury.

Authors:  Joseph E Perosky; Jonathan R Peterson; Owulatobi N Eboda; Michael D Morris; Stewart C Wang; Benjamin Levi; Kenneth M Kozloff
Journal:  J Orthop Res       Date:  2014-08-02       Impact factor: 3.494

6.  Towards non-invasive characterization of breast cancer and cancer metabolism with diffuse optics.

Authors:  David R Busch; Regine Choe; Turgut Durduran; Arjun G Yodh
Journal:  PET Clin       Date:  2013-07

7.  Singular value decomposition metrics show limitations of detector design in diffuse fluorescence tomography.

Authors:  Frederic Leblond; Kenneth M Tichauer; Brian W Pogue
Journal:  Biomed Opt Express       Date:  2010-11-29       Impact factor: 3.732

8.  Structure-inherent targeting of near-infrared fluorophores for parathyroid and thyroid gland imaging.

Authors:  Hoon Hyun; Min Ho Park; Eric A Owens; Hideyuki Wada; Maged Henary; Henricus J M Handgraaf; Alexander L Vahrmeijer; John V Frangioni; Hak Soo Choi
Journal:  Nat Med       Date:  2015-01-05       Impact factor: 53.440

Review 9.  The frontier of live tissue imaging across space and time.

Authors:  Qiang Huang; Aliesha Garrett; Shree Bose; Stephanie Blocker; Anne C Rios; Hans Clevers; Xiling Shen
Journal:  Cell Stem Cell       Date:  2021-04-01       Impact factor: 24.633

10.  Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions-in vitro study.

Authors:  Sravan Kumar Patel; Yang Zhang; John A Pollock; Jelena M Janjic
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.